We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AVTR Stock Flat Following the Close of Divestiture Deal With Audax
Read MoreHide Full Article
Avantor, Inc. (AVTR - Free Report) recently announced that it has closed the divestiture of its clinical services business to Audax Private Equity (Audax) in a transaction valued at approximately $650 million.
The transaction not only strengthens AVTR’s balance sheet and reduces interest expenses but also enables the company to sharpen its focus on strategic growth opportunities in its lab and production businesses.
Likely Trend of AVTR Stock Following the News
Following the announcement, shares of the company closed flat at $24.73 on Friday.
In the year-to-date period, AVTR shares have rallied 8.3% against the industry’s decline of 2.5%. The S&P 500 increased 22.9% in the same time frame.
Image Source: Zacks Investment Research
More on AVTR’s Deal With Audax
In August, AVTR signed a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively known as Clinical Services), to Audax.
Avantor expects the transaction to result in approximately $500 million in after-tax cash proceeds and a reduction of approximately $50 million in capitalized leases. Management intends to utilize the after-tax proceeds for debt paydown, which will likely strengthen the company's balance sheet and reduce interest expenses.
Per management, the agreement is an important step for Avantor as it continues to optimize its portfolio in line with its new operating model. The deal is expected to accelerate its ongoing business transformation and sharpen the company’s strategic focus.
Favorable Industry Prospects for AVTR
Per a report by Future Market Insights, the global analytical laboratory service market is estimated to be $472.6 million in 2024 and is projected to be worth $1,375 million by 2034 at a CAGR of 11.3%. Factors like the growing popularity of point-of-care testing and the increasing adoption of smart lab infrastructure with sensor networks are likely to drive the market.
Given the market potential, the latest divestiture will likely provide a significant impetus to Avantor’s lab and production businesses.
Boston Scientific’s shares have gained 70.4% in the past year. Estimates for the company’s earnings per share (EPS) have remained constant at $2.40 for 2024 and $2.71 for 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average beat of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for DaVita’s 2024 EPS have remained constant at $9.99 in the past 30 days. Shares of the company have surged 103.3% in the past year compared with the industry’s growth of 39.2%. DVA’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 24.2%. In the last reported quarter, it delivered an earnings surprise of 4.9%.
Estimates for Masimo’s 2024 EPS have risen 0.3% in the past 30 days. Shares of the company have surged 80.4% in the past year compared with the industry’s 26.2% growth. MASI’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 4.1%. In the last reported quarter, it delivered an earnings surprise of 11.7%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AVTR Stock Flat Following the Close of Divestiture Deal With Audax
Avantor, Inc. (AVTR - Free Report) recently announced that it has closed the divestiture of its clinical services business to Audax Private Equity (Audax) in a transaction valued at approximately $650 million.
The transaction not only strengthens AVTR’s balance sheet and reduces interest expenses but also enables the company to sharpen its focus on strategic growth opportunities in its lab and production businesses.
Likely Trend of AVTR Stock Following the News
Following the announcement, shares of the company closed flat at $24.73 on Friday.
In the year-to-date period, AVTR shares have rallied 8.3% against the industry’s decline of 2.5%. The S&P 500 increased 22.9% in the same time frame.
Image Source: Zacks Investment Research
More on AVTR’s Deal With Audax
In August, AVTR signed a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively known as Clinical Services), to Audax.
Avantor expects the transaction to result in approximately $500 million in after-tax cash proceeds and a reduction of approximately $50 million in capitalized leases. Management intends to utilize the after-tax proceeds for debt paydown, which will likely strengthen the company's balance sheet and reduce interest expenses.
Per management, the agreement is an important step for Avantor as it continues to optimize its portfolio in line with its new operating model. The deal is expected to accelerate its ongoing business transformation and sharpen the company’s strategic focus.
Favorable Industry Prospects for AVTR
Per a report by Future Market Insights, the global analytical laboratory service market is estimated to be $472.6 million in 2024 and is projected to be worth $1,375 million by 2034 at a CAGR of 11.3%. Factors like the growing popularity of point-of-care testing and the increasing adoption of smart lab infrastructure with sensor networks are likely to drive the market.
Given the market potential, the latest divestiture will likely provide a significant impetus to Avantor’s lab and production businesses.
AVTR’s Zacks Rank & Stocks to Consider
AVTR carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Boston Scientific (BSX - Free Report) , DaVita (DVA - Free Report) and Masimo (MASI - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 70.4% in the past year. Estimates for the company’s earnings per share (EPS) have remained constant at $2.40 for 2024 and $2.71 for 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average beat of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for DaVita’s 2024 EPS have remained constant at $9.99 in the past 30 days. Shares of the company have surged 103.3% in the past year compared with the industry’s growth of 39.2%. DVA’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 24.2%. In the last reported quarter, it delivered an earnings surprise of 4.9%.
Estimates for Masimo’s 2024 EPS have risen 0.3% in the past 30 days. Shares of the company have surged 80.4% in the past year compared with the industry’s 26.2% growth. MASI’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 4.1%. In the last reported quarter, it delivered an earnings surprise of 11.7%.